https://charts.traderzeitung.de/phases/US4525EP2001 string(1434) "{"isin":"US4525EP2001","name":"Immunic Inc","stock_id_xnas":132475561,"stock_id_xnys":132475562,"generated_at":"2026-09-24 01:33:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":10.75,"close_at":"2026-09-21 15:27:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":10.83,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":0.7442},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":10.78,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":-0.4617},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":11,"close_at":"2026-09-22 23:09:00","complete":true,"perf_pct":2.0408}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":9.37,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-14.8182},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Immunic Aktie News & Nachrichten

[WKN: A428WY | Symbol: IMUX]

Realtimekurs

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.